Product Details: Myo-Inositol Trispyrophosphate (ITPP) Liquid

Myo-Inositol Trispyrophosphate (ITPP) is the laboratory-made derivative of a naturally occurring compound, Myo-Inositol. Myo-Inositol is naturally produced in organisms that consist of a 6-carbon cyclic alcohol. When three pyrophosphate groups are added to its -OH side, it converts into a Myo-Inositol Trispyrophosphate compound.

This converted ITPP has the potential to enter cell membranes in preclinical models and influence hemoglobin affinity for oxygen. Due to this potential, it has been studied in hypoxic conditions (low oxygen) and in topics related to oncology, cardiology, metabolism, and insulin resistance in preclinical models. 

How does ITPP work?

According to preclinical research, ITPP has the potential to cross the cell membranes of red blood cells in organisms. This process reduces the hemoglobin’s grip on oxygen, allowing it to release more oxygen to various cells in preclinical models. This mechanism may enhance oxygenation in multiple tissues of preclinical models where oxygen is scarce.

Properties of Myo-Inositol Trispyrophosphate Liquid (ITPP)

• Alternative Names: Myo-inositol trispyrophosphate, 116EYZ0PPX, 802590-64-3, DTXCID301514847, DTXSID301029636
• Molecular Formula: C6H12O21P6
• Molecular Weight: 605.99 g/mol
• CAS Number: 802590-64-3

Potential Experimental Benefits of Myo-Inositol Trispyrophosphate (ITPP) Liquid

The potential benefits of Myo-Inositol Trispyrophosphate (ITPP) liquid observed in preclinical models are as follows:

Potential Improvement in Tissue Oxygenation:

In experiments on preclinical models, ITPP liquid has shown potential to improve oxygenation. This oxygenation effect occurs when ITPP liquid crosses the cell membranes of cells and reduces hemoglobin affinity for oxygen in preclinical models. With reduced hemoglobin affinity, hemoglobin releases the stored oxygen to various tissues in preclinical models during experiments.  

Potential Influence on Mitigation of Hypoxia:

ITPP has also been studied for its potential to mitigate hypoxia (a condition of low oxygen levels) in preclinical models during laboratory experiments. During hypoxia, the cells in preclinical models are unable to receive sufficient oxygen supply.

ITPP liquid triggers hemoglobin in preclinical models to release oxygen to tissues that lack oxygen supply. This mitigates hypoxia and affects the activities of HIF-alpha cells (HIF-alpha cells are oxygen-sensitive) in preclinical models during laboratory experiments.  

Influences Anti-Tumor Activities: 

Besides being used in hypoxic conditions, ITPP has also been experimented with for its influence on anti-tumor activities in preclinical models. In cancer studies, tissues are unable to receive sufficient oxygen supply. This triggers premature angiogenesis (the formation of abnormal blood vessels) in preclinical models, worsening the condition further.

ITPP liquid helps by providing sufficient oxygen, thereby reducing the abnormal formation of blood vessels in preclinical models. Due to this potential impact, ITPP is being studied for its anti-tumor activities in preclinical models during laboratory experiments. 

Note: Myo-Inositol Trispyrophosphate (ITPP) is not approved by the FDA for medical use or as a dietary supplement. This compound is intended strictly for research purposes only and is not for human consumption.

Why Choose BehemothLabz to Buy Myo-Inositol Trispyrophosphate (ITPP) Liquid

Start your research journey by ordering our premium quality Myo-Inositol Trispyrophosphate (ITPP) liquid online.

At BehemothLabz, we offer third-party verified and tested Myo-Inositol Trispyrophosphate (ITPP) liquid for sale. Our products are aligned with the industrial standards and the requirements of researchers, maximizing the chances of optimal results. Additionally, we provide our customers with a 24/7 customer representative service.

Additionally, our prices for products are reasonable and within the purchasing range, while maintaining high quality. Our products can be delivered nationally and internationally, with free shipping available for orders exceeding $100.

BehemothLabz Disclaimer

Please make sure you go through the Terms and Conditions, and please familiarize yourself with them, as they are important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.

Buying the product means you agree to our Terms and Conditions. You can contact our awesome customer service team at support@behemothlabz.com if you are not fully satisfied with the product.

All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Reference Links

PubChem. (2026). Myo-inositol trispyrophosphate. Nih.gov; PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Myo-inositol-trispyrophosphate

Oknińska, M., Bouchra El‐Hafny‐Rahbi, Paterek, A., Mackiewicz, U., Silva, C. C., Klaudia Brodaczewska, Michał Mączewski, & Kieda, C. (2020). Treatment of hypoxia‐dependent cardiovascular diseases by myo‐inositol trispyrophosphate (ITPP)‐enhancement of oxygen delivery by red blood cells. Journal of Cellular and Molecular Medicine, 24(3), 2272–2283. https://doi.org/10.1111/jcmm.14909

‌Martyna Krzykawska-Serda, Dariusz Szczygiel, Szymon Gaweł, Agnieszka Drzal, Małgorzata Szczygiel, Kmiec, M. M., Mackiewicz, A., Kieda, C., & Martyna Elas. (2023). Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)–Local pO2 study in murine tumors. PLoS ONE, 18(5), e0285318–e0285318. https://doi.org/10.1371/journal.pone.028531